These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
852 related articles for article (PubMed ID: 31300059)
1. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Huang M; Yan C; Xiao J; Wang T; Ling R Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059 [TBL] [Abstract][Full Text] [Related]
2. Effects of Coexistent BRAF Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854 [TBL] [Abstract][Full Text] [Related]
3. [ Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125 [TBL] [Abstract][Full Text] [Related]
4. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation. Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050 [TBL] [Abstract][Full Text] [Related]
5. Single Point Mutations in Pediatric Differentiated Thyroid Cancer. Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297 [TBL] [Abstract][Full Text] [Related]
6. Lymph Node Metastasis in Papillary Thyroid Carcinoma, A Study of BRAF V600E and TERT Promoter Mutations. Soeratman AR; Kartini D; Andinata B; Harahap AS; Sudarsono NC Asian Pac J Cancer Prev; 2024 Jun; 25(6):2043-2049. PubMed ID: 38918666 [TBL] [Abstract][Full Text] [Related]
7. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011 [TBL] [Abstract][Full Text] [Related]
8. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer. Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897 [TBL] [Abstract][Full Text] [Related]
9. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population. Argyropoulou M; Veskoukis AS; Karanatsiou PM; Manolakelli A; Kostoglou-Athanassiou I; Vilaras G; Karameris A; Liadaki K Pathol Oncol Res; 2020 Jan; 26(1):347-354. PubMed ID: 30361901 [TBL] [Abstract][Full Text] [Related]
10. Coexistence of Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646 [No Abstract] [Full Text] [Related]
11. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110 [TBL] [Abstract][Full Text] [Related]
12. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases. Fakhruddin N; Jabbour M; Novy M; Tamim H; Bahmad H; Farhat F; Zaatari G; Aridi T; Kriegshauser G; Oberkanins C; Mahfouz R Sci Rep; 2017 Jul; 7(1):4666. PubMed ID: 28680105 [TBL] [Abstract][Full Text] [Related]
13. The synergic effect of BRAF Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763 [TBL] [Abstract][Full Text] [Related]
14. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937 [TBL] [Abstract][Full Text] [Related]
15. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population. Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112 [TBL] [Abstract][Full Text] [Related]
17. A mutation panel comprising BRAF Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379 [TBL] [Abstract][Full Text] [Related]
18. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032 [TBL] [Abstract][Full Text] [Related]
19. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077 [TBL] [Abstract][Full Text] [Related]
20. The Genetic Duet of Liu J; Liu R; Shen X; Zhu G; Li B; Xing M J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570 [No Abstract] [Full Text] [Related] [Next] [New Search]